Latest filings (excl ownership)
D/A
Indefinite amount in investment fund, sold $1.51 bn, 27 investors
29 Dec 23
D/A
Indefinite amount in investment fund, sold $1.51 bn, 27 investors
30 Dec 22
D/A
Indefinite amount in investment fund, sold $1.11B, 26 investors
4 Jan 22
D/A
Indefinite amount in investment fund, sold $675.08M, 24 investors
7 Jan 21
D/A
Indefinite amount in investment fund, sold $413.83M, 19 investors
10 Jan 20
D/A
Indefinite amount in investment fund, sold $224.03M, 18 investors
11 Jan 19
D/A
Indefinite amount in investment fund, sold $224.03M, 18 investors
8 Dec 17
D/A
Indefinite amount in investment fund, sold $212.03M, 17 investors
21 Sep 16
D/A
Indefinite amount in investment fund, sold $64.76M, 13 investors
12 Nov 14
D/A
Indefinite amount in investment fund, sold $41.66M, 14 investors
8 Nov 13
D/A
Indefinite amount in investment fund, sold $37.66M, 12 investors
8 Nov 12
D/A
Indefinite amount in investment fund, sold $36.16M, 12 investors
8 Nov 11
D
Indefinite amount in investment fund, sold $34.91M, 12 investors
21 Oct 10
D/A
Indefinite amount in investment fund, sold $29.16M, 12 investors
15 Oct 09
SC TO-T/A
Third party tender offer statement (amended)
27 Mar 09
DFAN14A
Additional proxy materials by non-management
23 Mar 09
DFAN14A
Additional proxy materials by non-management
20 Mar 09
SC TO-T/A
Third party tender offer statement (amended)
20 Mar 09
DFAN14A
Additional proxy materials by non-management
13 Mar 09
DFAN14A
Additional proxy materials by non-management
13 Mar 09
DFAN14A
Additional proxy materials by non-management
12 Mar 09
DEFC14A
Proxy in contested solicitation
10 Mar 09
DFAN14A
Additional proxy materials by non-management
10 Mar 09
SC TO-T/A
Third party tender offer statement (amended)
9 Mar 09
CORRESP
Correspondence with SEC
5 Mar 09
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 09
DFAN14A
Additional proxy materials by non-management
10 Feb 09
DFAN14A
Additional proxy materials by non-management
6 Feb 09
SC TO-T/A
Third party tender offer statement (amended)
6 Feb 09
PRRN14A
Revised preliminary proxy statement filed by non-management
5 Feb 09
PRRN14A
Revised preliminary proxy statement filed by non-management
29 Jan 09
CORRESP
Correspondence with SEC
20 Jan 09
DFAN14A
Additional proxy materials by non-management
15 Jan 09
SC TO-C
Information about tender offer
15 Jan 09
PREC14A
Preliminary proxy with contested solicitation
13 Jan 09
DFAN14A
Additional proxy materials by non-management
9 Jan 09
REGDEX
Notice of sale of securities
2 Oct 08
REGDEX
Notice of sale of securities
13 Feb 03
Latest ownership filings
4
MARK N LAMPERT
18 Jun 24
4
MARK N LAMPERT
10 Jun 24
SC 13G
Celcuity Inc.
10 Jun 24
SC 13G
Foghorn Therapeutics Inc.
30 May 24
SC 13G
PIERIS PHARMACEUTICALS, INC.
17 May 24
SC 13G
PIERIS PHARMACEUTICALS, INC.
17 May 24
4
MARK N LAMPERT
13 May 24
SC 13D/A
MoonLake Immunotherapeutics
5 Mar 24
SC 13G/A
enGene Holdings Inc.
22 Feb 24
SC 13G/A
Aclaris Therapeutics, Inc.
14 Feb 24
SC 13G/A
AILERON THERAPEUTICS INC
14 Feb 24
SC 13G/A
Annexon, Inc.
14 Feb 24
SC 13G/A
Aravive, Inc.
14 Feb 24
SC 13G/A
ASLAN Pharmaceuticals Ltd
14 Feb 24
SC 13G/A
BIONOMICS LIMITED/FI
14 Feb 24
SC 13G/A
Cidara Therapeutics, Inc.
14 Feb 24
SC 13G/A
Cullinan Oncology, Inc.
14 Feb 24
SC 13G/A
Centessa Pharmaceuticals plc
14 Feb 24
SC 13G/A
Crinetics Pharmaceuticals, Inc.
14 Feb 24
SC 13G/A
CytomX Therapeutics, Inc.
14 Feb 24
SC 13G/A
DELCATH SYSTEMS, INC.
14 Feb 24
SC 13G/A
Eledon Pharmaceuticals, Inc.
14 Feb 24
SC 13G/A
Elevation Oncology, Inc.
14 Feb 24
SC 13G/A
89bio, Inc.
14 Feb 24
SC 13G/A
4D Molecular Therapeutics, Inc.
14 Feb 24
SC 13G/A
GH Research PLC
14 Feb 24
SC 13G/A
Galmed Pharmaceuticals Ltd.
14 Feb 24
SC 13G/A
IDEAYA Biosciences, Inc.
14 Feb 24
SC 13G/A
Ikena Oncology, Inc.
14 Feb 24
SC 13G/A
iTeos Therapeutics, Inc.
14 Feb 24
SC 13G/A
Janux Therapeutics, Inc.
14 Feb 24
SC 13G/A
Jasper Therapeutics, Inc.
14 Feb 24
SC 13G/A
Kura Oncology, Inc.
14 Feb 24
SC 13G/A
LEXICON PHARMACEUTICALS, INC.
14 Feb 24
SC 13G/A
Merus N.V.
14 Feb 24
SC 13G/A
Molecular Templates, Inc.
14 Feb 24
SC 13G/A
Protagonist Therapeutics, Inc
14 Feb 24
SC 13G/A
Pyxis Oncology, Inc.
14 Feb 24
SC 13G/A
Revolution Medicines, Inc.
14 Feb 24
SC 13G/A
Tyra Biosciences, Inc.
14 Feb 24